Eduardo Guillén

Biography

    Dr. Eduardo Guillén is the Director of Protein Therapeutics at EpiVax, Inc. Dr. Guillén obtained his PhD in Chemistry at the University of Buenos Aires in the laboratory of Prof. Roberto Couso, where he studied biosynthesis and trafficking of lysosomal enzymes. After studying Golgi transporters of nucleotide-sugars in Carlos Hirshberg’s laboratory at UMass Medical School, Dr. Guillén went to Herman Eisen’s laboratory at MIT to study cross-presentation mechanisms of exogenous antigens by dendritic cells. Working for Stressgen Biotechnologies in the same laboratory, he studied immune response mechanisms to a therapeutic vaccine against Human Papilloma Virus. Dr. Guillén moved to the Hidde Ploegh laboratory at the Whitehead Institute to study immune response to viruses and intracellular pathogens, as well as antibody response to extracellular antigens. In collaboration with Dr. Marcus Altfeld at the Ragon Institute, he applied the high-throughput methods for screening antigen-specific T and B cells to T cell response to HIV in elite controllers. Dr. Guillén now leads the biotherapeutics research at EpiVax, with a focus on immune response modulators based on EpiVax’s proprietary Tregitope technology which alleviate or prevent conditions arising from autoimmune diseases or transplants. With a team of collaborators, he is also perfecting methods for in vitro high-throughput screening of the immune response to biotherapeutics.  

Research Interest